GlassScriptPhysician profile
Everett R Forman
NPI 1528061967
$3,419.20
in general payments reported to CMS, 2019-2025
21 companies · $153 in 2025
The $153 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,491 · 2020: $506 · 2021: $56.85 · 2023: $19.17 · 2024: $194 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $365.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $610.88 | 2019-2024 | |
| Allergan, INC. | $403.45 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $361.54 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $232.40 | 2019-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $225.78 | 2019 | |
| Amarin Pharma, INC. | $215.76 | 2019 | |
| Lilly USA, LLC | $165.77 | 2019-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $155.49 | 2019-2021 | |
| Amgen INC. | $145.08 | 2019 | |
| Glaxosmithkline, LLC. | $135.80 | 2019 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Pfizer INC. | $119.43 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.20 | 2024 | |
| Sanofi-Aventis U.S. LLC | $103.52 | 2019 | |
| Novartis Pharmaceuticals Corporation | $102.95 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $64.43 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $55.33 | 2020 | |
| Arbor Pharmaceuticals, INC. | $27.40 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.19 | 2024 | Tradjenta, Jardiance |
| Seqirus USA INC | $16.87 | 2019 | |
| Nabriva Therapeutics, Plc | $14.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Everett Forman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.